Pharmacokinetics of New Antiretroviral Agents in HIV-Infected Pregnant Women Study on Drug Levels During and After Pregnancy (PANNA)

What this Trial Is About

This research aims to understand how pregnancy affects the way certain antiretroviral medications behave in the body of HIV-infected pregnant women. Since pregnancy can change how drugs are absorbed and processed, the study focuses on measuring drug levels during pregnancy, especially in the third trimester, when these changes are most noticeable. The goal is to see if current medication doses provide adequate exposure for pregnant women living with HIV. The study will examine a range of antiretroviral agents including Etravirine, Emtricitabine, Tenofovir, Atazanavir, Fosamprenavir, Darunavir, Tipranavir, Indinavir, Abacavir, Raltegravir, Enfuvirtide, Maraviroc, Dolutegravir, Elvitegravir/cobicistat, Rilpivirine, TAF, Darunavir/cobicistat, Doravirine, Bictegravir, and long-acting injectables like Cabotegravir/rilpivirine. Participants must be on a combination antiretroviral therapy (cART) regimen containing at least one of these agents for at least two weeks before the first pharmacokinetic evaluation. The study will record how drug concentrations change in the blood during the third trimester and again 4 to 6 weeks after delivery. Participants will be involved in pharmacokinetic monitoring where blood samples will be taken to measure medication levels. The main outcome measured is the plasma concentration of the drugs during pregnancy compared to after delivery. Participants need to follow food intake recommendations if applicable and provide informed consent. The study is designed to ensure safety by excluding those with conditions affecting drug metabolism or severe anemia. The total duration includes assessments in the third trimester and postpartum period to understand medication exposure throughout this critical time.

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.